4-Hydrazinobenzenesulfonamide

We are 4-Hydrazinobenzenesulfonamide CAS:4392-54-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:4-Hydrazinobenzenesulfonamide
CAS.NO:4392-54-5
Synonyms:4-Hydrazinobenzenesulfonamide
p-Hydrazinobenzenesulfonamide
Phenylhydrazine-4-sulfonamide
4-HYDRAZINO-BENZENSULFONAMIDE
4-AMINOSULFONYLPHENYLHYDRAZINE
4-(sulfamyl)phenylhydrazine
 
Physical and Chemical Properties:
Density 1.5±0.1 g/cm3
Boiling Point 434.7±47.0 °C at 760 mmHg
Melting Point 158-159ºC(lit.)
Molecular Formula C6H9N3O2S
Molecular Weight 187.220
Flash Point 216.7±29.3 °C
 
Specification:
Appearance:Off-white to light beige powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Celecoxib(CAS:169590-42-5).

4-Hydrazinobenzenesulfonamide


Related News: China is fast-tracking approval for innovative drugs at home in a bid to offer more and cheaper options to patients, as many in the rapidly aging country struggle to find alternatives to costly treatments sold by multinational pharmaceutical firms for chronic diseases.(1R, 8S) -8-Amino-4- (imidazo [1,2-b] piridazin-1-ium-1-ilmetil) -7-ox o-2-tiabiciclo [4.2.0] oct-4-eno -5-carboxilato CAS:167271-60-5 China is fast-tracking approval for innovative drugs at home in a bid to offer more and cheaper options to patients, as many in the rapidly aging country struggle to find alternatives to costly treatments sold by multinational pharmaceutical firms for chronic diseases.Dimethoxy(methyl)silane China is fast-tracking approval for innovative drugs at home in a bid to offer more and cheaper options to patients, as many in the rapidly aging country struggle to find alternatives to costly treatments sold by multinational pharmaceutical firms for chronic diseases.2-Bromobutane This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.

Related Products
Product Name
2,3-Dichloroquinoxaline View Details
2,6-Dichloro-3-fluoropyridine View Details
3-Nitro-4-hydroxyquinoline View Details
N-Boc-glycine Ethyl Ester manufacturer (R)-3-(3-Fluoro-4-morpholinophenyl)-5-(hydroxymethyl)oxazolidin-2-one manufacturer 4-Bromo-3-nitrotoluene manufacturer 2,6-Dichloropurine manufacturer a,a-Dichloro-N,N-Diethylacetylacetamide manufacturer